Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Operations: 2020-2025

Historic Cash from Operations for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$4.5 million.

  • Insight Molecular Diagnostics' Cash from Operations rose 18.59% to -$4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.0 million, marking a year-over-year decrease of 11.40%. This contributed to the annual value of -$20.7 million for FY2024, which is 11.20% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Cash from Operations of -$4.5 million as of Q3 2025, which was up 28.30% from -$6.3 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Cash from Operations registered a high of -$3.8 million during Q3 2023, and its lowest value of -$13.3 million during Q1 2022.
  • Moreover, its 3-year median value for Cash from Operations was -$5.5 million (2024), whereas its average is -$5.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 82.35% in 2021, then spiked by 66.93% in 2023.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Cash from Operations stood at -$7.1 million in 2021, then crashed by 36.56% to -$9.6 million in 2022, then soared by 54.15% to -$4.4 million in 2023, then dropped by 21.50% to -$5.4 million in 2024, then increased by 18.59% to -$4.5 million in 2025.
  • Its last three reported values are -$4.5 million in Q3 2025, -$6.3 million for Q2 2025, and -$5.9 million during Q1 2025.